Michael Ciarametaro

Effects of drug price negotiation stemming from title 1 of H.R. 3, the lower drug costs now act of 2019, on spending and revenues related to part D of medicare Congressional Budget Office.. Letter to the Honorable Frank Pallone Jr. . Available from: https://www.cbo.gov/system/files/2019-10/hr3ltr.pdf?wpisrc=nl_health202&wpmm=1

Michael Ciarametaro & Craig Garthwaite & Craig Mitton & Sue Peschin & Joel White Health Affairs October 13, 2021 Josie Norris/The Saginaw News via AP Interest in lowering drug costs for patients and taxpayers has led to the recent reintroduction of HR3—the Elijah E. Cummings Lower Drug Costs Now Act. As a result, the potential enactment of international reference pricing is once again the subject of intense policy debate among policy makers and broader health care stakeholders.

Interest in lowering drug costs for patients and taxpayers has led to the recent reintroduction of HR3—the Elijah E. Cummings Lower Drug Costs Now Act. As a result, the potential enactment of international reference pricing is once again the subject of intense policy debate among policy makers and broader health care stakeholders. This proposal would link the price that Medicare pays for select drugs to prices paid by other countries, with these negotiated prices also extending to private plans.